Scroll through social media or walk past a busy chemist's shop and you may see offers and promotions for medicines that are supposed to be sold only on a doctor's prescription. India's Union Health Ministry now wants to close a gap in the rules that has allowed some of that promotion to slip through.
On 9 October 2026, the Ministry of Health and Family Welfare announced a proposed amendment to the Drugs Rules, 1945, that would extend existing restrictions on advertising prescription-only medicines to drug retailers, wholesalers and distributors.
What the draft rule says
Under the current framework, pharmaceutical manufacturers cannot advertise drugs listed in Schedule H, Schedule H1 and Schedule X without prior sanction from the Central Government. According to the ministry, however, the rules have not explicitly covered businesses that sell and distribute these medicines.
The draft, notified through Gazette Notification G.S.R. 861(E) dated 28 September 2026, proposes inserting a new sub-rule (22) under Rule 65 of the Drugs Rules. It would apply to holders of licences to sell, stock, exhibit, offer for sale or distribute drugs, including retail and wholesale licence holders.
The proposed wording is short: no advertisement of drugs specified in Schedule H, Schedule H1 or Schedule X shall be made except with the previous sanction of the Central Government.
The ministry says the proposal follows recommendations from the 93rd meeting of the Drugs Technical Advisory Board (DTAB), held on 16 February 2026.
Why the government says it is needed
According to the ministry, the amendment aims to:
- strengthen regulatory oversight across the pharmaceutical supply chain
- discourage unauthorised promotion of prescription medicines
- reduce the risks of inappropriate self-medication
The ministry specifically mentions medicines that need medical supervision, including certain antibiotics, psychotropic medicines and other prescription-only drugs.
What Schedule H, H1 and X mean
These schedules are lists in India's drug rules that set out which medicines need a prescription and how tightly they are controlled. According to the Health Ministry, drugs in Schedule H and Schedule X must be sold by retail only on the prescription of a registered medical practitioner.
- Schedule H covers a long list of common prescription medicines.
- Schedule H1, introduced in 2013, includes certain third- and fourth-generation antibiotics, certain habit-forming drugs and anti-TB drugs. Pharmacies must record each sale in a separate register, with the prescriber's and patient's names, the drug and the quantity, and the pack must carry a red "Rx" symbol and a boxed warning.
- Schedule X is a much shorter list of medicines that carry the tightest controls because of their potential for misuse.
If you are unsure whether a medicine needs a prescription, ask a pharmacist or your doctor.
Why self-medication is a concern
Using prescription medicines without medical advice can mean taking the wrong drug, the wrong amount or a drug that interacts badly with something else you take. With antibiotics, there is a wider public health cost too.
The World Health Organization says the misuse and overuse of antimicrobials are driving the development and spread of drug-resistant infections. WHO estimates that bacterial antimicrobial resistance was associated with more than 4.7 million deaths globally in 2021, and that about 1 in 6 laboratory-confirmed bacterial infections worldwide were resistant to antibiotics in 2023.
Promotional offers on antibiotics or sedatives can encourage people to buy them for problems they do not treat, such as viral colds and flu, or to keep them at home "just in case".
What happens next
The rule is still a draft. The ministry has invited objections and suggestions from stakeholders and the public within 30 days from the date copies of the Gazette containing the draft are made available to the public. The Gazette copy is dated 5 October 2026. The notification says objections and suggestions can be addressed to the Under Secretary (Drugs) at the ministry or emailed to the address given in the Gazette. The Central Government will consider submissions before finalising the amendment.
It is not yet known exactly when a final rule might take effect, or how it would be enforced online and offline. Those details will matter for pharmacies, online sellers and consumers alike.
What it means for you
Whatever happens to the draft, a few principles already apply:
- Do not buy prescription medicines because of an advert or discount. Medicines are not ordinary consumer products.
- Do not take antibiotics without a doctor's advice. They do not work against viruses, and misuse fuels resistance.
- Finish or stop a prescribed course only as your doctor advises.
- Be cautious with sedatives and sleeping pills. Some carry a risk of dependence and should be used only under medical supervision.
- Tell your doctor about everything you take, including over-the-counter and herbal products, to avoid harmful interactions.
- Report suspicious promotions. If you see prescription drugs being pushed with offers or without asking for a prescription, you can raise it with your state drug control authority.
FAQ
Is this rule already in force? No. It is a draft amendment open for public comment. The government will consider objections and suggestions before finalising it.
Who will the new rule apply to? Holders of licences to sell, stock, exhibit, offer for sale or distribute drugs, including retail and wholesale licence holders.
Can manufacturers already advertise prescription drugs? Not without prior Central Government sanction. The draft would extend the same requirement to sellers and distributors.
Does this affect over-the-counter medicines? The draft refers only to drugs in Schedules H, H1 and X.
Sources
- PIB: Union Health Ministry proposes tighter curbs on advertising of prescription drugs by retailers and wholesalers (9 October 2026)
- Gazette of India: Draft Drugs (Amendment) Rules, 2026, G.S.R. 861(E) (PDF)
- PIB: Rules for selling of drugs under Schedule H1 (2013)
- WHO fact sheet: Antimicrobial resistance
